Showing 5501-5510 of 8729 results for "".
- LifeNet Health Acquires Bioventus's Wound Care Divisionhttps://practicaldermatology.com/news/lifenet-health-acquires-bioventuss-wound-care-division/2461711/LifeNet Health announced the expantion of its portfolio with the acquisition of Bioventus' wound care division. Financial terms of the acqusition were not disclosed. "Non-healing wounds are a modern health care crisis," LifeNet Health President an
- Evolus Acquires Exclusive US Distributor Rights to Evolysse Line of Dermal Fillershttps://practicaldermatology.com/news/evolus-acquires-exclusive-us-distributor-rights-to-evolysse-line-of-dermal-fillers/2461710/Evolus has entered into a definitive agreement to be the exclusive US distributor of a line of five dermal fillers currently in late-stage development. Evolus is partnering with Symatese, a privately held French company, to introduce the Evolysse line to its US customers beginning
- American Academy of Dermatology Survey Shows Generation Z Adults are Unfamiliar with Sunburn and Tanning Riskshttps://practicaldermatology.com/news/american-academy-of-dermatology-survey-shows-generation-z-adults-are-unfamiliar-with-sunburn-and-tanning-risks/2461708/A recent American Academy of Dermatology survey of more than 1,000 US adults revealed that many Generation Z adults, ages 18-25, are unaware of the risks associated with overexposure to the sun and believe tanning myths, according to an AAD news release. According to the surv
- Lycored: Study Shows Preventive Effects and Protective Potential of Astaxanthin on Collagen Damagehttps://practicaldermatology.com/news/lycored-study-shows-preventive-effects-and-protective-potential-of-astaxanthin-on-collagen-damage/2461706/A study recently found that Lycored's astaxanthin prevented against collagen damage from neutrophils, discovering its potential to protect collagen and enhance skin health. The study,
- FDA Set to Review Ortho Derm's Triple Combo Acne Gelhttps://practicaldermatology.com/news/fda-set-to-review-ortho-derms-triple-combo-acne-gel/2461705/The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Ortho Dermatologics’ investigational IDP-126 (clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%) Gel. The Prescription Drug User Fee Act (PDUFA) action date is set for October 20, 2023, accordin
- DermaSensor’s Skin Cancer Device May Help Primary Care Providers Spot Skin Cancerhttps://practicaldermatology.com/news/dermasensors-skin-cancer-device-may-help-internists-spot-skin-cancer/2461703/DermaSensor Inc.’s nove
- AI In Action: Rubedo Life Sciences Introduces RLS-1496 as a Potential First-in-Class Derm Drughttps://practicaldermatology.com/news/ai-in-action-rubedo-life-sciences-introduces-rls-1496-as-a-potential-first-in-class-derm-drug/2461699/Rubedo Life Sciences has nominated RL
- Study: DecisionDx-Melanoma May Lead to Earlier Melanoma Detection, Decreased Metastatic Tumor Burdenhttps://practicaldermatology.com/news/study-decisiondx-melanoma-may-lead-to-earlier-melanoma-detection-decreased-metastatic-tumor-burden/2461698/The use of Castle Biosciences, Inc. DecisionDx-Melanoma test results to guide radiological surveillance may lead to improved patient outcomes, according to a new study in Archives of Dermatological Research. The new study, conducted at three National Cancer Institute-desig
- U.S. FDA Grants Breakthrough Therapy Designation to Spevigo for the prevention of GPP Flareshttps://practicaldermatology.com/news/us-fda-grants-breakthrough-therapy-designation-to-spevigo-for-the-prevention-of-gpp-flares-1/2461694/The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation (BTD) to Spevigo for the prevention of generalized pustular psoriasis (GPP) flares, Boehringer Ingelheim reports. This designation follows the Center for Drug Evaluation (CDE) of China National Medic
- MRA Announces $6.3 Million in Grants to Advance Melanoma Preventionhttps://practicaldermatology.com/news/mra-announces-63-million-in-grants-to-advance-melanoma-prevention/2461691/The Melanoma Research Alliance (MRA) announced a new $6.3 million commitment to fund melanoma resear